Literature DB >> 15347486

Imiquimod 5 percent cream and the treatment of cutaneous malignancy.

Daniel Navi1, Arthur Huntley.   

Abstract

Imiquimod is a novel synthetic compound that is a member of the imidazoquinolone family of drugs. This class of drugs, which also includes a more potent member, resimiquimod (R-848), is unique having the properties of topical immune response modifiers and stimulators. Imiquimod resembles a nucleoside analogue and is known for its potent induction of endogenous antiviral pro-inflammatory mediators. This article is a review of the relevant literature as it relates to the off-label applications of imiquimod 5 percent cream for treatment of cutaneous preneoplastic and neoplastic conditions including its recently approved indication for treating actinic keratoses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347486

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  18 in total

1.  [Extramammary Paget disease: successful therapy with imiquimod 5% cream].

Authors:  G Wagner; M Heine; M M Sachse
Journal:  Hautarzt       Date:  2012-01       Impact factor: 0.751

2.  Toll-like receptors and cutaneous melanoma.

Authors:  Ilaria Coati; Serena Miotto; Irene Zanetti; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

3.  Extramammary Paget's disease of the scrotum with complete response to imiquimod and photodynamic therapy.

Authors:  Tyler M Bauman; Ilana S Rosman; David M Sheinbein
Journal:  BMJ Case Rep       Date:  2018-03-05

4.  Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions.

Authors:  Christina Megill; Timothy Wilkin
Journal:  Semin Colon Rectal Surg       Date:  2017-04-26

5.  Pigmented basal cell carcinoma successfully treated with 5% Imiquimod cream.

Authors:  Vandana Mehta; C Balachandran
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

6.  Aldara activates TLR7-independent immune defence.

Authors:  Anne Walter; Matthias Schäfer; Virginia Cecconi; Claudia Matter; Mirjana Urosevic-Maiwald; Benedetta Belloni; Nicola Schönewolf; Reinhard Dummer; Wilhelm Bloch; Sabine Werner; Hans-Dietmar Beer; Alexander Knuth; Maries van den Broek
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 7.  Vitamin D and Vitamin D Analogs as Adjuncts to Field Therapy Treatments for Actinic Keratoses: Current Research and Future Approaches.

Authors:  Zafer Sattouf; Steven J Repas; Jeffrey B Travers; Craig A Rohan
Journal:  J Skin Cancer       Date:  2021-06-19

Review 8.  Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

Authors:  Luke A J O'Neill; Clare E Bryant; Sarah L Doyle
Journal:  Pharmacol Rev       Date:  2009-05-27       Impact factor: 25.468

9.  A case report of imiquimod topical therapy as treatment for cutaneous metastasis of breast cancer.

Authors:  Anthony L Nguyen; Esther G Chong; Joanne Lee; Saied Mirshahidi; Hamid Mirshahidi
Journal:  Rare Tumors       Date:  2021-06-24

Review 10.  Imiquimod - Its role in the treatment of cutaneous malignancies.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.